^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    2d
    Bispecific Antibodies and Antibody-Drug Conjugates in Advanced Gastric Adenocarcinoma. (PubMed, Cancers (Basel))
    Along with these developments in drug therapy, more therapies directed at CLDN18.2, HER2, MSI, EGFR, HER3 and trophoblast cell-surface antigen 2 (TROP2) are underway. Here we review future areas in advanced GAC, including zanidatamab's potential role in HER2-positive advanced GAC and deciphering the abundance of anti-CLDN18.2, extending beyond investigative therapies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CLDN18 (Claudin 18)
    |
    HER-2 positive
    |
    Ziihera (zanidatamab-hrii)
    3d
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2028 --> Sep 2028 | Initiation date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    3d
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=400, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    4d
    BGB-A317-316: A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=351, Recruiting, BeOne Medicines
    Trial initiation date
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium
    6d
    IKS014-01: IKS014 in Advanced Solid Tumors That Express HER2 (clinicaltrials.gov)
    P1, N=165, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
    |
    caxmotabart entudotin (IKS014)
    8d
    Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. (PubMed, Am Soc Clin Oncol Educ Book)
    This review outlines the evolving therapeutic landscape of gastric and gastroesophageal junction cancers, spanning perioperative immunotherapy, newly validated molecular targets, and next-generation drug development platforms. By integrating biomarker-driven strategies with innovative modalities, such as antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor-T-cell therapy, and vaccines, we highlight how precision therapeutics are reshaping treatment paradigms across resectable and advanced disease.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    8d
    REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (clinicaltrials.gov)
    P1/2, N=21, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    8d
    MDX-2001-101: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=285, Recruiting, ModeX Therapeutics, An OPKO Health Company | N=115 --> 285
    Enrollment change • First-in-human
    10d
    Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Sep 2026 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    Talzenna (talazoparib) • Lonsurf (trifluridine/tipiracil)
    15d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=572, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    15d
    UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA). (PubMed, ESMO Gastrointest Oncol)
    Recently, perioperative durvalumab in combination with chemotherapy (ctx) has shown improved event-free survival in biomarker-unselected patients with resectable EGA. UCCL-IKF-NeoART is an international, open-label, non-randomized phase Ib/II platform trial evaluating T-DXd in sequential cohorts, each combining the drug with a different ctx regimen. Every cohort includes an initial safety run-in phase.
    P1/2 data • Journal • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)